While Teva is initially known for its generics business, the company is shifting its strategy to build a more innovative ...

Discover six companies advancing promising treatments for pulmonary hypertension beyond vasodilators, changing the standards of care.

Delve into Labiotech's October oncology roundup and find out about the news that caught our attention this last month.

Join leading experts to explore practical strategies for designing and delivering rare disease clinical trials in Europe.

People with polyendocrine metabolic ovarian syndrome (PMOS) are affected by hormone imbalances, impacting everything from mood to fertility. The cause of the condition is unknown, but the recent name ...

For years, macrocyclic drugs have occupied a niche space in the pharmaceutical landscape, offering drugmakers a way to tackle biological targets that conventional small molecules struggle to reach.

Vision loss remains one of the leading causes of disability worldwide, with millions affected by inherited retinal diseases, age-related macular degeneration, and diabetic eye disease. While existing ...

Spain’s biotech ecosystem is no longer short of companies. The number of biotech firms reached 1,119 in 2025, up 10.4% in a year, while investment hit a record €408 million ($456,6 million). Investors ...